CHATSWORTH, Calif.--(BUSINESS WIRE)--CHAD Therapeutics, Inc. (AMEX:CTU) today reported that its independent registered accountants, Rose, Snyder & Jacobs, had qualified their opinion on the Company’s March 31, 2008, financial statements as disclosed in the Company’s Form 10-K filed with the Securities and Exchange Commission on June 27, 2008. The qualification is based on doubts about the Company’s ability to continue as a going concern and the need to raise additional financing to support the launch of the products the Company is developing for the sleep disorder market, as described in Note 1 to the above-mentioned financial statements.
